Naqvi et al developed a prognostic model for patients with the myelodysplastic syndrome (MDS). This incorporates the patient's comorbidity into a score for predicting overall survival. The authors are from the University of Texas M.D. Anderson Cancer Center in Houston.
Parameters:
(1) age in years
(2) comorbidity by the Adult Comorbidity Evaluation -27 (ACE-27)
(3) myelodysplasia IPSS
|
Parameter |
Finding |
Points |
|
age in years |
<= 65 years of age |
0 |
|
|
> 65 years of age |
2 |
|
comorbidity |
none |
0 |
|
|
mild or moderate |
1 |
|
|
severe |
3 |
|
IPSS |
low or intermediate-1 |
0 |
|
|
intermediate-2 |
2 |
|
|
high |
3 |
where:
• Points were obtained by dividing the coefficients from the multivariate analysis by 0.3.
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 8
• The higher the score the worse the survival.
|
Total Score |
Risk Group |
Median Survival |
Percent Survival at 4 Years |
|
0 or 1 |
low |
43 months |
45% |
|
2 to 4 |
intermediate |
23 months |
24% |
|
5 to 8 |
high |
9 months |
6% |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
